Revenue: As of FY2026 Q1, the actual value is USD 7.024 M.EPS: As of FY2026 Q1, the actual value is USD -0.03.EBIT: As of FY2026 Q1, the actual value is USD 14.9 K.<h3>Segment Revenue</h3><ul><li>Physical Therapy and Rehabilitation Products: $4,161,586 for the three months ended September 30, 2025, compared to $4,218,354 for the same period in 2024.</li><li>Orthopedic Soft Bracing Products: $2,835,716 for the three months ended September 30, 2025, compared to $3,356,988 for the same period in 2024.</li><li>Other: $26,725 for the three months ended September 30, 2025, compared to $26,907 for the same period in 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: $201,857 for the three months ended September 30, 2025, compared to $366,648 for the same period in 2024.</li><li>Gross Profit: $1,731,629 for the three months ended September 30, 2025, compared to $1,980,807 for the same period in 2024.</li><li>Operating Loss: $88,463 for the three months ended September 30, 2025, compared to $250,996 for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: $93,317 for the three months ended September 30, 2025, compared to net cash provided by operating activities of $100,646 for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: $529,017 for the three months ended September 30, 2025, compared to net cash used in financing activities of $306,121 for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to address challenges by implementing cost reduction initiatives, streamlining operational processes, pursuing new revenue streams through product diversification, and transitioning production of the majority of its therapeutic modalities from a contract manufacturer to internal operations.</li><li>Non-Core Business: The company is evaluating its current inventory position and working to reduce excess inventory exposure by promoting discounted prices to convert the excess inventory to cash.</li><li>Priority: The company aims to mitigate factors giving rise to substantial doubt about its ability to continue as a going concern by successfully implementing strategic actions, although there is no guarantee of success.</li></ul>

Dynatronics | 10-Q: FY2026 Q1 Revenue: USD 7.024 M